Monitoring Glucose Levels During Assisted Reproduction in Infertile Women Using Continuous Glucose Monitoring Devices

What this Trial Is About

Infertility affects about 20% of couples of reproductive age worldwide, leading to increased use of assisted reproductive technologies ART. This research aims to continuously observe blood glucose changes during ART treatment in infertile women using continuous glucose monitoring CGM. The goal is to explore whether glucose variation influences assisted reproduction outcomes and to improve clinical pregnancy and live birth rates through tailored treatment. Participants will wear two FreeStyle Libre Pro Flash CGM devices during key periods of their ovarian stimulation. The first sensor collects baseline glucose data before starting ovulation induction, and the second sensor tracks glucose continuously during the ovulation induction cycle for 14 days. This protocol allows detailed glucose monitoring throughout the ART regimen. During the study, glucose levels will be carefully monitored and recorded, including mean sensor glucose, time within target glucose range, and glucose variability. The study lasts about two months during the assisted reproductive treatment period. Researchers will use this data to understand glucose patterns and their potential impact on ART success, supporting individualized care for patients undergoing infertility treatments.

Glucose Pattern in Infertile Women Receiving Assisted Reproduction Using Continuous Glucose Monitoring